New Study Shows Powerful Promise for Vaccine Therapy in Earlier Prostate Cancer

Anonymous

Guest
New Study Shows Powerful Promise for Vaccine Therapy in Earlier Prostate Cancer
2/13/13

Dr. Emmanuel Antonarakis, from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, explains a new study outcome combining androgen deprivation therapy (ADT) with an immunotherapy vaccine, Provenge (sipuleucel-T), in the hope of having greater impact when given to men with "biochemically-recurrent prostate cancer." The study is being reported at the 2013 American Society of Clinical Oncology (ASCO) GU Conference in Orlando.

In this first study testing sequencing of therapy with Provenge and ADT, Dr. Antonarakis explains positive indications that using ADT first followed by Provenge, could be a powerful combination and a possible road to a cure for some men. He stresses, however, that further study is needed. Dr. Antonarakis shares details in this interview with Patient Power's Andrew Schorr.

http://www.patientpower.info/video/new-study-shows-powerful-promise-for-vaccine-therapy-in-earlier-
prostate-cancer/?autoplay=1&utm_source=health-topic-alert&utm_medium=email&utm_campaign=apc-2013&utm_content=watch-now
 


















I am hearing a lot of excitement from the docs that the ADT followed by provenge clinical study. This would move us ahead of all the other available drugs and quadruple the available patient population.